| Methods |
2‐week placebo run‐in; inclusion criteria= SBP 160‐200 mm Hg and DBP 95‐120 mm Hg at 2 consecutive measurements; 8‐week double‐blind treatment |
| Participants |
Captopril 50 mg: n=42(23 males,19 females); mean age=52.8(10.6) years; baseline supine SBP=175.5(8.9) mm Hg, DBP=104.5(4.4) mm Hg;
Placebo: n=83(47 males,36 females); mean age=52.8(9.0) years; baseline supine SBP=172.0(7.7) mm Hg, DBP=102.5(3.8) mm Hg |
| Interventions |
Captopril 50 mg once daily;
Placebo |
| Outcomes |
Trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change for SBP and DBP; SBP data from Figure 1, p. 91S; DBP data from Figure 2, p. 91S; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
